Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT

Read More

Sun Pharma recalls eye drops in India after contamination scare

"Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I9GNHCo
via IFTTT

Read More

TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Read More

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT

Read More

As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent Pharmaceuticals

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman Mehta leads the firm with an ambitious future vision. He spearheaded a significant acquisition and focuses on weightloss drugs. Mehta emphasizes making the right strategic decisions for success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aa2ZNnG
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6yfHqpD
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xmdxj2f
via IFTTT

Read More